DekaBank Deutsche Girozentrale - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 195 filers reported holding REVANCE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.35 and the average weighting 0.2%.

Quarter-by-quarter ownership
DekaBank Deutsche Girozentrale ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,012
-52.8%
86,1000.0%0.00%
-60.0%
Q2 2023$2,142
-19.4%
86,1000.0%0.01%
-28.6%
Q1 2023$2,657
+66.2%
86,1000.0%0.01%
+75.0%
Q4 2022$1,599
-99.9%
86,1000.0%0.00%
-42.9%
Q3 2022$2,209,000
+81.8%
86,1000.0%0.01%
+75.0%
Q2 2022$1,215,000
+139.6%
86,100
+229.9%
0.00%
+300.0%
Q1 2022$507,000
+8.3%
26,100
-7.4%
0.00%0.0%
Q4 2021$468,000
-75.1%
28,200
-58.3%
0.00%
-80.0%
Q3 2021$1,880,000
-4.7%
67,6000.0%0.01%
-16.7%
Q2 2021$1,972,000
+6.1%
67,6000.0%0.01%0.0%
Q1 2021$1,859,000
+8.8%
67,600
+7.1%
0.01%0.0%
Q4 2020$1,708,000
+47.0%
63,100
+36.3%
0.01%
+20.0%
Q3 2020$1,162,000
+111.3%
46,300
+15.8%
0.01%
+66.7%
Q3 2019$550,000
-45.5%
40,000
-50.0%
0.00%
-40.0%
Q2 2019$1,010,000
+19.2%
80,000
+183.7%
0.01%
-16.7%
Q1 2018$847,000
+254.4%
28,200
+107.4%
0.01%
+100.0%
Q1 2016$239,000
-51.9%
13,600
-2.9%
0.00%
-50.0%
Q4 2015$497,000
+39.2%
14,000
+16.7%
0.01%
+50.0%
Q3 2015$357,000
-3.0%
12,000
+4.3%
0.00%0.0%
Q2 2015$368,000
+60.0%
11,500
+3.6%
0.00%
+33.3%
Q1 2015$230,00011,1000.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 3,342,047$94,714,00024.58%
Palo Alto Investors LP 2,673,313$75,762,0003.97%
Evolutionary Tree Capital Management, LLC 89,348$2,532,0001.93%
RICE HALL JAMES & ASSOCIATES, LLC 1,121,152$31,773,0001.12%
ArrowMark Colorado Holdings LLC 2,964,135$84,004,0000.65%
Rhenman & Partners Asset Management AB 220,000$6,235,0000.51%
Fosun International Ltd 233,841$6,627,0000.43%
OSTERWEIS CAPITAL MANAGEMENT INC 174,970$4,959,0000.30%
ESSEX INVESTMENT MANAGEMENT CO LLC 76,671$2,173,0000.27%
Tekla Capital Management LLC 213,808$6,059,0000.21%
View complete list of REVANCE THERAPEUTICS INC shareholders